Lianya Pharmaceutical Opens Subscription, Deeply Cultivated in the CRO Services Field for Many Years

On September 28, Lianya Pharmaceutical opened for subscription at an issue price of RMB 7 per share, with a subscription cap of 18,500 shares and a price-to-earnings ratio of 27.99 times. It is listed on the Shenzhen Stock Exchange, with CICC acting as its sponsor. According to the prospectus, the company is a research and development-driven high-tech enterprise primarily engaged in the research, development, production, and sales of complex pharmaceutical formulations.